EpiAxis Therapeutics and Canada s University Health Network have entered a collaboration to study a new epigenetics approach to prostate cancer treatment.
EpiAxis Therapeutics has announced a pioneering clinical study, showing that an epigenetic inhibitor combined with chemotherapy can treat metastatic cancer.
EpiAxis Therapeutics appoints new chief science officer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Operator
Welcome to the Q1 2021 Athenex, Inc. Earnings Conference Call. My name is Richard, and I ll be your operator for today s call. [Operator Instructions]
I am now going to call over Mr. Steven Rubis, Senior Director, Investor Relations. Steven, you may begin.
Steven Rubis
Investor Relations
Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenex s business as well as a review of financial results for the first quarter of 2021. The news release detailing the results crossed the wire earlier this morning and is available on the company s website. A replay of this call will also be archived on the company website. During the conference call, the company will make projections or forward-looking statements regarding future events, including statements about financial, business and clinical milestones anticipated in fiscal year 2021 and beyond. We encourage you to review the company s past and future filings with the SEC, which